Cargando…

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

PURPOSE: A novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab [Single Tremelimumab Regular Interval Durvalumab (STRIDE)] has demonstrated a favorable benefit-risk profile in the phase I/II Study 22 (NCT02519348) and phase III HIMALAYA study (NCT03298451). This study eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Xuyang, Kelley, Robin Kate, Khan, Anis A., Standifer, Nathan, Zhou, Diansong, Lim, KyoungSoo, Krishna, Rajesh, Liu, Lu, Wang, Kun, McCoon, Patricia, Negro, Alejandra, He, Philip, Gibbs, Megan, Kurland, John F., Abou-Alfa, Ghassan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Clinical Trials: Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932581/ https://www.ncbi.nlm.nih.gov/pubmed/36477555 http://dx.doi.org/10.1158/1078-0432.CCR-22-1983

Ejemplares similares

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
por: Voss, Martin H., et al.
Publicado: (2022)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
por: Hamid, Omid, et al.
Publicado: (2023)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
por: Chouieri, Toni
Publicado: (2023)

An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023)

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
por: Hecht, Markus, et al.
Publicado: (2020)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
por: Aggarwal, Charu, et al.
Publicado: (2023)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab
por: Dey, Agnish, et al.
Publicado: (2022)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer
por: Doki, Yuichiro, et al.
Publicado: (2022)

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
por: Lee, Jung-Yun, et al.
Publicado: (2019)

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
por: Santa-Maria, Cesar August, et al.
Publicado: (2018)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
por: Manji, Gulam A., et al.
Publicado: (2021)

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
por: Verset, Gontran, et al.
Publicado: (2022)

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
por: Fahmy, Omar, et al.
Publicado: (2022)

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
por: Mahmood, Syed S., et al.
Publicado: (2018)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
por: Lee, Dae Ho, et al.
Publicado: (2023)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
por: Leighl, Natasha B, et al.
Publicado: (2021)

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
por: Ahmed, Zunirah, et al.
Publicado: (2023)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
por: Bahig, Houda, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_befefsc0seq6upikpee40c85vh